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Abstract
 
Ischemic brain injury resulting from stroke arises from primary neuronal losses and by inflamma-
tory responses. Previous studies suggest that erythropoietin (EPO) attenuates both processes.
Although EPO is clearly antiapoptotic for neurons after experimental stroke, it is unknown
whether EPO also directly modulates EPO receptor (EPO-R)–expressing glia, microglia, and
other inflammatory cells. In these experiments, we show that recombinant human EPO (rhEPO;
5,000 U/kg body weight, i.p.) markedly reduces astrocyte activation and the recruitment of
leukocytes and microglia into an infarction produced by middle cerebral artery occlusion in rats.
In addition, ischemia-induced production of the proinflammatory cytokines tumor necrosis
factor,  interleukin 6, and monocyte chemoattractant protein 1 concentration is reduced by
 
 
 
50% after rhEPO administration. Similar results were also observed in mixed neuronal-glial co-
cultures exposed to the neuronal-selective toxin trimethyl tin. In contrast, rhEPO did not in-
hibit cytokine production by astrocyte cultures exposed to neuronal homogenates or modulate
the response of human peripheral blood mononuclear cells, rat glial cells, or the brain to li-
popolysaccharide. These findings suggest that rhEPO attenuates ischemia-induced inflammation by
reducing neuronal death rather than by direct effects upon EPO-R–expressing inflammatory cells.
Key words: stroke • erythropoietin • inﬂammation • apoptosis • ischemia
 
Introduction
 
Inflammatory responses within the central nervous system
are triggered by widely diverse etiologies and can provide
either beneficial or harmful results. For example, brain or
spinal cord injuries are characterized by a central necrotic
core surrounded by a variably sized region populated by
injured cells (the penumbra) at risk for further degeneration
over hours to days. If uncontrolled, self-perpetuating in-
flammatory reactions within the penumbra significantly
expand the extent of infarcted tissue.
Recent interest has focused upon the role of local pro-
tective mechanisms reducing the penumbral volume. One
promising endogenous neuroprotective is the cytokine
erythropoietin (EPO) and its receptor (EPO-R). These
proteins are abundant in brain and spinal cord (1) and are
significantly up-regulated by metabolic stress (2, 3). In this
role, a local system independent of the renal–bone marrow
axis represents a biological substrate for “preconditioning,”
a phenomenon in which mild hypoxic stress increases tissue
resistance to subsequent severe hypoxia (4).
We have previously shown that exogenously adminis-
tered recombinant human EPO (rhEPO) effectively crosses
the blood-brain barrier and provides neuroprotection in
rodent models of cerebral ischemia and brain traumatic
injury (5). Mechanistically, rhEPO rescues neurons within
the penumbra from apoptosis (6), which is also observed in
vitro for primary neuronal cultures and neuronal cell lines
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(6, 7) exposed to hypoxic stress. However, inflammatory
mechanisms contribute importantly to the brain damage of
cerebral ischemia, such as by the production of neurotoxins,
including nitric oxide, and reactive oxygen species by im-
mune cells (for review see reference 8). It is notable that a
number of cells participating in inflammatory responses to
ischemia (e.g., astrocytes and microglia) express the EPO-R
(9, 10). However, it is currently unclear how extensively
an endogenous neuroprotective system can modulate isch-
emia-induced inflammation and if so, whether this results
from a direct antagonism of inflammatory processes and/or
indirectly via reduced neuronal death. Specifically, does
EPO-reduced injury depend upon a dual activation of both
antiapoptotic and antiinflammatory activity?
In this study, we evaluated the effect of rhEPO adminis-
tration on the inflammatory component in a three vessel rat
model of middle cerebral artery (MCA) ischemia reperfu-
sion. Specifically, rhEPO was administered at the time of
MCA occlusion (MCAO) and the brains were evaluated
histologically for inflammatory responses 24 h after reperfu-
sion by immunostaining using markers of glial and leuko-
cyte/microglial activation. We also determined the tissue
concentrations of cytokines known to play important roles
in brain inflammation (i.e., TNF, IL-6, and monocyte
chemoattractant protein 1 [MCP-1]). These results were
compared with those obtained using an in vivo model of
inflammation where TNF production is not related to neu-
rodegeneration, but is rather induced in the brain by expo-
sure to LPS, an endotoxin associated with Gram-negative
bacteria. Parallel in vitro studies assessed the effects of
rhEPO on TNF production by peripheral blood mononu-
clear cells (PBMCs) or glial cells directly stimulated by LPS,
as well as in a neuronal-glial coculture model of ischemic
injury. The results indicate that rhEPO is a selective antiin-
flammatory cytokine, active only in the setting of neuronal
degeneration, by limiting neuronal apoptosis.
 
Materials and Methods
 
Materials.
 
Trimethyltin (TMT) chloride was purchased from
Società Italiana Chimici. rhEPO (epoetin alfa, Procrit) was from
Ortho Biotech. All other reagents were from Sigma-Aldrich.
Procedures involving animals were conducted in conformity
with institutional guidelines in compliance with national and in-
ternational laws and policies.
 
MCAO.
 
Surgery was performed on male Crl:CD(SD)BR
rats weighing 250–280 g (Charles River Laboratories) as previ-
ously described (5). The core temperature was maintained at
36.5–37.5
 
 
 
C by use of a homeothermic heating blanket con-
nected to a rectal probe. PBS or rhEPO (5,000 U/kg body
weight, i.p.) was administered at the time of occlusion of the
contralateral carotid artery. TNF and IL-6 levels were quantified
in brain cortex homogenates (11) and MCP-1 was measured us-
ing a commercial ELISA (Biosource International). All cytokine
levels were measured at their respective peak time of production
(8 h for TNF and 24 h for IL-6 and MCP-1).
 
Immunohistochemistry.
 
24 h after MCAO, perfused brains
were sectioned (30 
 
 
 
m) in the transverse plane on a cryostat. Free
floating sections were processed for immunoreactivity using anti–
 
glial fibrillary acidic protein (GFAP) mouse monoclonal (1:250;
Boehringer) and anti–cd11b (MRC OX-42) mouse monoclonal
antibodies (1:50; Serotec), according to the protocols of Houser
et al. (12) and the manufacturer, respectively.
 
Intracerebroventricular (icv) Injection of LPS.
 
Male CD-1 mice
(22–25 g; Charles River Laboratories) were injected icv with 2.5
ug LPS via a 28-gauge needle (13) and TNF was measured in
brain homogenates 90 min later (11). In additional experiments,
rhEPO was administered either systemically (100 U/mouse, i.p.,
24 h and 30 min before LPS) or centrally (100 U/mouse, icv, at
the same time of LPS injection).
 
PBMCs.
 
PBMCs were prepared from buffy coats obtained
from healthy donors using standard Ficoll-Hypaque gradients.
Cells were resuspended at 2.5 
 
  
 
10
 
6
 
/ml in RPMI 1640 medium
with 10% FCS and cultured for 4 h with 1 ug/ml LPS. TNF was
assayed in the supernatants as described above.
 
Primary Cultures of Glial Cells and Hippocampal Neurons.
 
Pri-
mary cultures of glia and neurons were prepared as previously de-
scribed (14). All experiments were performed on 2–3-wk-old
glial cell cultures with 97% astrocytes and 3% microglia, as as-
sessed by immunocytochemistry for GFAP and 
 
Griffonia
 
 
 
simplicifo-
lia
 
 isolectin B
 
4
 
. Hippocampal neuronal cultures were established
from 18-d rat fetuses and 160,000 cells were plated onto individ-
ual polyornithine-coated coverslips. After 24 h, coverslips were
transferred to dishes containing a glial monolayer in neuron
maintenance medium (Dulbecco’s modified Eagle’s medium and
Ham’s nutrient mix F12 supplemented with 5 
 
 
 
g/ml insulin, 100
 
 
 
g/ml transferrin, 100 
 
 
 
g/ml putrescin, 30 nM Na selenite, 20
nM progesterone, and 100 U/ml penicillin) supplemented with
5 
 
 
 
M cytosine arabinoside. Coverslips were inverted and arranged
such that the hippocampal neurons faced the glia monolayer with
paraffin dots on the coverslips creating a narrow gap that allowed
the diffusion of soluble substances between the cell layers. These
conditions allowed for the maintenance of differentiated neuronal
cultures with 
 
 
 
98% homogeneity. Cells were then treated for
24 h with 1 
 
 
 
M TMT with or without 10 U/ml rhEPO. Viabil-
ity was assessed by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphen-
yltetrazolium bromide assay (15) and the supernatants were as-
sayed for TNF.
To obtain homogenates from differentiated hippocampal neu-
rons, glass coverslips with 6–8-d-old cultured hippocampal cells
were scraped off in their culture medium and the resultant sus-
pension was sonicated in ice twice for 15 s. Glial cells were then
exposed to homogenates or to neuronal culture medium in the
presence or absence of 10 U/ml rhEPO for 24 h at 37
 
 
 
C before
TNF determination. Each sample of glial cell was exposed to the
homogenate obtained by 
 
 
 
300,000 cells. The neuronal homoge-
nate itself contained no appreciable TNF (3.4 
 
  
 
0.4 pg/ml).
 
Results
 
EPO Reduces Inflammatory Cell Infiltration after Ischemia.
 
Consistent with our previous report (5), 24 h after of the in-
duction of MCAO, the ipsalateral cerebral cortex exhibited
extensive tissue injury within the territory of the MCA in sa-
line-treated ischemic rats. The volume of injury was reduced
by 
 
 
 
75% after the administration of rhEPO (5,000 U/kg
body weight, i.p.). Within the region of the frontal cortex
supplied by the MCA, brain sections obtained from saline-
treated ischemic rats were abundantly populated by activated
glia, as assessed by GFAP immunoreactivity (Fig. 1). In con-
trast, reactive glia were markedly reduced in either rhEPO-T
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treated ischemic or sham-operated rats (Fig. 1). Microglia
within these brain regions were identified by staining with
anti-CD11b (OX-42) and found to be numerous and hyper-
trophic within and around the infarction core, extending far
into the ischemic penumbra of saline-treated ischemic rats
(Fig. 2). In contrast, reactive microglia were observed rarely
and only within a limited cortical volume immediately adja-
cent to the necrotic core in rhEPO-treated rats. Within the
central core, the same antibody also identified a small num-
ber of cells morphologically consistent with monocytes and
macrophages (not depicted). These observations are consis-
tent with an ischemia-induced reactive astrocytosis and re-
cruitment of mononuclear/microglial cells, which were all
markedly reduced in rhEPO-treated ischemic rats.
 
rhEPO Attenuates the Production of Inflammatory Cytokines
after MCAO.
 
The appearance of inflammatory cells within
the penumbra after MCAO could depend in part upon the
production of proinflammatory cytokines. When measured
at their respective peak time of production, TNF (Fig. 3 A),
MCP-1 (Fig. 3 B), and IL-6 (Fig. 3 C) were all detected at
high concentrations within the ischemic brain cortex. In
contrast, systemic administration of rhEPO (5,000 U/kg
body weight, i.p. immediately after MCAO) was associated
with a significant reduction of the production of all three cy-
tokines, whereas their levels in the contralateral cortex of the
same animals were below the limit of detection (Fig. 3).
 
rhEPO Does Not Inhibit LPS-induced TNF Production.
 
To evaluate the possibility that rhEPO might directly affect
TNF production, we investigated whether rhEPO would
modify LPS-induced TNF release in vitro or in vivo. As
shown in Fig. 4 A, 10 U/ml rhEPO did not attenuate LPS-
induced TNF production in cultured glial cells, nor did it
Figure 1. rhEPO dramatically attenuates glial activation in rat MCAO
model. Frontal cortical sections adjacent to the region of infarction
stained by GFAP antibody. S, Sham operated rat; C, ischemic rat treated
with PBS; E, ischemic rat treated with rhEPO. Activated astrocytes are
visualized by their GFAP  processes (C). Note the marked reduction in
number as well as staining intensity in a representative rhEPO-treated
animal (E). Bar, 200  m.
Figure 2. rhEPO inhibits leukocyte infiltration and microglia activation in
rat MCAO. Brain sections stained by OX-42 antibody. Representative
equivalent areas of the penumbra from an ischemic rat treated with PBS
(C), or with rhEPO (E). In the ischemic cerebral hemisphere, the cellular
staining is especially prominent around the infarcted tissue in both treatment
groups, but is much denser and extends further in the saline-treated
group. Bar, 100  m.
Figure 3. rhEPO decreases inflammatory cytokine levels in ischemic
brain. TNF (A) was measured 8 h after MCAO. MCP-1 (B) and IL-6
(C) were measured 24 h after MCAO. Open bars, ischemia plus PBS;
solid bars, ischemia plus rhEPO. No cytokines were detectable in control,
nonischemic, and brains (not depicted). Data are mean   SE. n   9. *, P  
0.05; **, P  0.01 versus ischemia plus PBS by Student’s t test. Cytokine
levels in the contralateral cortex were below the limit of detection
(TNF   1 U/g tissue; IL-6   150 U/g; MCP-1   24 pg/g).
Figure 4. rhEPO does not affect LPS-induced TNF production in
vitro or in vivo. (A) TNF production by glial cells cultured with 0.1  g/ml
LPS for 24 h. (B) Brain TNF levels in mice injected icv with 2.5  g/
mouse of LPS. 100 U/mouse rhEPO was given either icv at the same
time of LPS (time 0) or as a systemic pretreatment (i.p. 24 h and 30 min
before the icv administration of LPS). Open bars, LPS plus PBS; solid
bars, LPS plus EPO.T
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modify TNF production induced in human PBMCs by
1 
 
 
 
g/ml LPS (for 4 h) for rhEPO concentrations up to 100
U/ml (three donors studied; unpublished data). Similarly,
administration of rhEPO either systemically (100 U/mouse,
i.p., 24 h and 30 min before LPS) or centrally (100 U/mouse,
icv, at the same time of LPS injection) did not effect brain
TNF levels stimulated in vivo by direct icv injection of 2.5
 
 
 
g LPS in mice (Fig. 4 B).
 
rhEPO Inhibits TNF Production by Glial Cells after Neu-
ronal Death in Neuronal-Glial Cocultures.
 
We have previ-
ously demonstrated that the selective neurotoxin TMT
increases glial TNF production and release as a strict
function of neuronal death from apoptosis (16). To eval-
uate whether the rhEPO-mediated differences in cyto-
kine levels in MCAO could be explained by reduction of
neuronal death rather than a primary effect on the inflam-
matory cells, mixed cultures of neurons and glia were ex-
posed to TMT in the presence or absence of rhEPO. As
shown in Fig. 5, 10 U/ml rhEPO significantly protected
neurons from the toxicity of 1 
 
 
 
m TMT evaluated 24 h
later, reducing cell death by 
 
 
 
50% (Fig. 5 A). In this
model in which the cell types are separated, neuronal cell
death stimulates the production of TNF by glial cells.
The addition of rhEPO significantly reduced the amount
of TNF produced (Fig. 5 B). In contrast, similar treat-
ment of neuron-depleted glial cultures by TMT failed to
stimulate TNF production. Finally, rhEPO did not affect
the astrocyte-derived TNF produced by exposure to neu-
ronal homogenates in the absence of cocultured neurons
(Fig. 5 C).
 
Discussion
 
Collectively, these data show that administration of
rhEPO in a rat model of cerebral focal ischemia markedly
reduces the influx of inflammatory cells into the region of
injury. By this mechanism, rhEPO attenuates the produc-
tion of proinflammatory cytokines, which in turn, results in
a much smaller volume of injury. This concept is supported
 
by the strong protective effect of anti-TNF antibodies in
reducing the volume of injury in this model (17).
However, unlike “classical” antiinflammatory cytokines
(e.g., IL-10 and IL-13) that inhibit TNF production directly
in vitro and in vivo (18, 19), rhEPO does not appear to di-
rectly affect TNF release in vitro (glial cells or PBMCs) or
in vivo (either administered centrally or systemically). Sig-
nificantly, a number of molecules have been identified that
do inhibit cytokine production after LPS exposure (e.g., cil-
iary neurotrophic factor [20], interleukin-10 [18], or neuro-
steroids [21]). Therefore, rhEPO exhibits selective activity
only in the setting of ischemic injury. That is, the inflamma-
tion-attenuating effects of rhEPO do not result from a direct
action upon inflammatory cells known to express EPO-R,
by blocking the release of cytokines.
Alternatively, rhEPO might exert its antiinflammatory
effects by preventing the generation of molecular signals by
injured neurons (e.g., the appearance of phosphatidylserine
within the cell membrane, known to be a critical signal for
the attraction and activation of microglia and astrocytes; 22,
23). The in vitro experiments using cocultures of glial and
neuronal cells, in which neuronal death is associated with
the release of factors that induce TNF release by glial cells
(16), provide convincing evidence that the antiinflamma-
tory action of rhEPO is, in fact, secondary to its neuropro-
tective activity. In this experimental system, neural death
was achieved by exposing the cells to TMT, a selective
neurotoxicant and a useful tool to induce glial activation
through neural degeneration. Although there are common
signaling pathways for inflammation and neuronal pro-
grammed cell death (e.g., caspase I is important in neuronal
apoptosis as well as processes inflammatory cytokines IL-1
and IL-18) the observations reported here suggest that such
a common mediator cannot be a target for rhEPO, as
rhEPO has no direct effect upon the release of cytokines by
inflammatory cells.
Even though rhEPO has no direct effect on proinflamma-
tory cytokine production, it does provide increased resistance
of cellular targets, e.g., neurons, to the effects of inflamma-
tion. It is notable that inflammation increases the ultimate
volume of cerebral injury by several mechanisms, including a
direct inhibition of local EPO production. In fact, although
EPO is endogenously produced in the brain after ischemia
(2, 3), its expression is markedly inhibited by inflammatory
cytokines (e.g., TNF; 10), IL-1, and IFN-
 
  
 
(24, 25), as well
as by reactive oxygen and nitrogen species (26, 27). On the
other hand, inflammatory cytokines such as TNF greatly in-
crease the level of expression of EPO-R in astrocytes and
neurons (10). In this way, the inhibition of endogenous EPO
by inflammatory cytokines and reactive oxygen species might
contribute to the role of these two classes of mediators in the
pathogenesis of ischemia and explain why exogenously ad-
ministered rhEPO is especially beneficial.
In summary, exogenously administered rhEPO confers a
strong antiinflammatory activity within the setting of ex-
perimental brain injury. In contrast, inflammation pro-
duced by nonneurological mechanisms, e.g., endotoxin,
are not affected by exposure to rhEPO. Our data support a
Figure 5. rhEPO prevents neuronal death-induced TNF production in
mixed neuron-glia cocultures. (A) Percentage of neural cell death induced by
1  M TMT without or with treatment with 10 U/ml rhEPO. (B) Release of
TNF from glial cells exposed to 1  M TMT in the presence (gray bars) or
absence (black bars) of neurons, with or without 10 U/ml rhEPO. (C) Cyto-
kine production by glial cells exposed to the products of neuronal homo-
genates with or without rhEPO. Neuronal death, P   0.05 (Student’s t
test) versus TMT alone; TNF production, *, P   0.05 versus neurons
plus glia (ANOVA plus Tukey’s multiple comparison test). The same
experimental conditions were used for the three panels of this experiment.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
Villa et al. Brief Definitive Report
 
975
 
model wherein rhEPO attenuates neuronal injury inflam-
mation by reducing neuronal apoptosis and increasing resis-
tance to inflammatory injury rather than by a direct inhibi-
tion of cytokine release.
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